ライフサイエンスコーパス: biological therapy

1 of tumorigenesis and the design of rational biological therapy.

2 eous stimulation, novel drug approaches, and biological therapies.

3 rticularly those who do not respond to other biological therapies.

4 lytic VV in combination with conventional or biological therapies.

5 d use include the use of antimetabolites and biological therapies.

6 a combination of loco-regional and targeted biological therapies.

7 dvances in the fast expanding field of these biological therapies.

8 nse, and summarise the role of antibodies in biological therapies.

9 nt in surgical and radiation techniques, and biological therapies.

10 n of clinical trials should explore emerging biological therapies.

11 e of 33%, with use of topical therapy (60%), biological therapy (66%, mostly anti-tumor necrosis fact

12 al therapy was compared with chemotherapy or biological therapy alone.

13 e resulted in renewed interest in the use of biological therapies, although only subsets of individua

14 se-modifying antirheumatic drugs (DMARDs) to biological therapies and a more technical focus on dynam

15 ed patients with severe psoriasis initiating biological therapy and matched controls not receiving sy

16 lone individuals who receive chemotherapy or biological therapy and should be continued for 6-12 mont

17 There is a ying/yang to most biological therapies, and the balance of efficacy versus

18 Here we show that the cytotoxic biological therapy Apo2L/TRAIL can prime the tumor micro

19 Interventions: Biological therapy approved for psoriasis (adalimumab, e

20 Biological therapies are claiming a place in the routine

21 Given that biological therapies are exceedingly expensive and pose

22 icult tumour to treat, and response rates to biological therapies are less than 20%.

23 d treatments for PD have advanced, and newer biological therapies are now emerging.

24 ted vasculitis is increasing, and many novel biological therapies are now entering the drug developme

25 To review biological therapies as they pertain to the treatment of

26 With an increasing range of biological therapies available in the management of rheu

27 ts that compare response to chemotherapy and biological therapies between patients and zPDX.

28 ules, and accessory molecules are targets of biological therapy, but the relevance of these targets i

29 acizumab in combination with chemotherapy or biological therapy, compared with chemotherapy alone, wa

30 -dose biological drugs to 55 for combination biological therapy, compared with traditional DMARDs.

31 Biological therapies differ from chemotherapeutic approa

32 aches--including preliminary experience with biological therapies directed at tumor necrosis factor a

33 Recent studies of both nonbiological and biological therapies for arthritis-related uveitis are d

34 The development of approved biological therapies for autoimmune diseases provides ne

35 tegral to the potential development of novel biological therapies for autoinflammatory diseases, incl

36 and represent a critical step in developing biological therapies for degenerative disc disease.

37 The development of biological therapies for SLE parallels the increasing un

38 New biological therapies for treatment of severe asthma, tog

39 opportunities and risks inherent in a novel biological therapy for a progressive neurologic disease.

40 ase III trials can lead to approval of a new biological therapy for regenerative medicine.

41 The development of biological therapies has improved management of rheumato

42 Although biological therapy has shown promising clinical response

43 ey cancer is a devastating disease; however, biological therapies have achieved some limited success.

44 Several new biological therapies have been developed, which target s

45 Interleukin-2-based regimens of biological therapy have shown some clinical promise for

46 Targeted biological therapies hold tremendous potential for treat

47 Biological therapy holds much promise in SLE and as we l

48 The body of data supporting the use of biological therapies in inflammatory bowel disease conti

49 re is ongoing debate about the role of newer biological therapies in prevention, treatment or even as

50 of an inhibitory Lt betaR-Ig as a candidate biological therapy in demyelinating disorders, because i

51 tudy on the pharmacogenetics of FcgammaR and biological therapy in psoriasis suggest a role with clin

52 has been taken toward a more rational use of biological therapy in psoriasis.

53 S0008 (S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma) w

54 Biological therapies including antibodies, soluble recep

55 However, such biological therapies, including those targeting epiderma

56 ation associated with immune-suppressive and biological therapies is emerging to be an important caus

57 An intrinsic problem with developing new biological therapies is the difficulty in determining th

58 ns involved in the immunological pathways of biological therapy may account for the differences obser

59 for some profoundly deaf patients, potential biological therapies must extend hearing restoration to

60 nodal sites represent novel targets for the biological therapy of cancer.

61 FN-gamma and IL-4 and their potential in the biological therapy of renal cell carcinoma.

62 After successful biological therapy of Renca in BALB/c mice, we generated

63 on there has been particular interest in the biological therapy of these diseases.

64 Biological therapies offer tremendous potential in the t

65 patients with psoriasis a new and effective biological therapy option.

66 pies that pair antiangiogenic treatment with biological therapy or chemotherapy.

67 Biological therapies play an increasingly prominent role

68 Their lack of targets for hormonal/biological therapy presents significant clinical challen

69 reasingly diagnosed in patients treated with biological therapies such as monoclonal antibodies that

70 increase access to effective and life-saving biological therapies such as rituximab.

71 iles in assessing early treatment effects in biological therapies such as vaccines awaits further val

72 The effectiveness of biological therapies, such as anti-interleukin 6, in pat

73 eatment continues to be a challenge, but new biological therapies, such as humanised antibodies again

74 risk of viral reactivation when prescribing biological therapies, thereby facilitating the request f

75 nt experiments demonstrate the potential for biological therapies to regenerate or remyelinate axons

76 overy of inner ear function and suggest that biological therapies to treat deafness may be suitable f

77 as amalgam, composites, and metallic alloys, biological therapies utilize mesenchymal stem cells, del

78 acizumab in combination with chemotherapy or biological therapy was compared with chemotherapy or bio

79 The need for biological therapy will inevitably increase dramatically

80 In most patients, systemic administration of biological therapies with cytokines is associated with s

81 Objective: To investigate the association of biological therapy with changes in coronary artery disea